重新审视类固醇类药物和阿司匹林在急性川崎病治疗中的作用
Review the Role of Corticosteroids and Aspirin in the Treatment of Acute Kawasaki Disease
DOI: 10.12677/ACM.2020.107209, PDF,   
作者: 冯建英, 焦富勇, 杨 勇, 王 繁：陕西省人民医院儿童病院，陕西 西安
关键词: 川崎病；类固醇类药物；阿司匹林；Kawasaki Disease； Corticosteroids； Aspirin
摘要: 目前认为，口服大剂量阿司匹林(ASP) (80~100 mg/kg∙d)与小剂量ASP (3~5 mg/kg∙d)在改善川崎病(Kawasaki disease, KD)急性期冠状动脉预后方面，并没有明显的差异。类固醇类药物适用于冠状动脉损伤预后不良和使用静脉丙种球蛋白(IVIG)治疗的耐药KD患儿，无论是在高危患儿的早期治疗，还是静脉注射IVIG失败后的抢救治疗，类固醇类药物均是有效的，并且耐受性良好。
Abstract: There is no significant difference between oral high-dose aspirin (ASP) (80 - 100 mg/kg∙d) and low-dose ASP (3 - 5 mg/kg∙d) in improving coronary prognosis in the acute phase of Kawasaki disease (KD). Corticosteroids are suitable for KD children with poor prognosis of coronary artery injury and intravenous gamma globulin (IVIG) resistance. Corticosteroids are effective and well tolerated in both early treatment of high-risk children and salvage treatment after failure of intravenous IVIG.
文章引用：冯建英, 焦富勇, 杨勇, 王繁. 重新审视类固醇类药物和阿司匹林在急性川崎病治疗中的作用[J]. 临床医学进展, 2020, 10(7): 1391-1396. https://doi.org/10.12677/ACM.2020.107209

参考文献

[1] Chen, J.J., Ma, X.J., Liu, F., et al. (2016) Epidemiologic Features of Kawasaki Disease in Shanghai from 2008 through 2012. The Pediatric Infectious Disease Journal, 35, 7-12. [Google Scholar] [CrossRef] 
[2] Singh, S., Vignesh, P. and Burgner, D. (2015) The Epidemiology of Kawasaki Disease: A Global Update. Archives of Disease in Childhood, 100, 1084-1088. [Google Scholar] [CrossRef] [PubMed]
[3] Holman, R.C., Christensen, K.Y., Belay, E.D., et al. (2010) Racial/Ethnic Differences in the Incidence of Kawasaki Syndrome among Children in Hawaii. Hawaii Medical Journal, 69, 194-197.
[4] McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment and Long-Term Management of Kawasaki Disease. A Scientific Statement for Health Professionals from the American Heart Association. Circulation Journal, 135, e927-e999.
[5] Singh, S., Sharma, A. and Jiao, F.Y. (2016) Kawasaki Disease: Issues in Diagnosis and Treatment: A Developing Country Perspective. Indian Journal of Pediatrics, 83, 140-145. [Google Scholar] [CrossRef] [PubMed]
[6] Michihata, N., Matsui, H., Fushimi, K., et al. (2015) Guideline-Concordant Treatment of Kawasaki Disease with Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm. Clinical Pediatrics, 54, 1076-1080. [Google Scholar] [CrossRef] [PubMed]
[7] Terai, M. and Shulman, S.T. (1997) Prevalence of Coronary Artery Abnormalities in Kawasaki Disease Is Highly Dependent on Gamma Globulin Dose But Independent of Salicylate Dose. Journal of Pediatrics, 131, 888-893. [Google Scholar] [CrossRef] 
[8] Dhanrajani, A. and Yeung, R.S.M. (2017) Revisiting the Role of Steroids and Aspirin in the Management of Acute Kawasaki Disease. Current Opinion in Rheumatology, 29, 547⁃552. [Google Scholar] [CrossRef] 
[9] Gurbel, P.A., Bliden, K.P., DiChiara, J., et al. (2007) Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation, 115, 3156-3164. [Google Scholar] [CrossRef] 
[10] Dallaire, F., Fortier-Morissette, Z., Blais, S., et al. (2017) Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease. Pediatrics, 139, e20170098. [Google Scholar] [CrossRef] [PubMed]
[11] Durongpisitkul, K., Gururaj, V.J., Park, J.M., et al. (1995) The Prevention of Coronary Artery Aneurysm in Kawasaki Disease: A Meta-Analysis on the Efficacy of Aspirin and Immunoglobulin Treatment. Pediatrics, 96, 1057-1061.
[12] Furusho, K., Kamiya, T., Nakano, H., et al. (1992) Intravenous γ-Globulin for Kawasaki Disease. Acta Paediatrica Japonica, Overseas Edition, 33, 799-804. [Google Scholar] [CrossRef] 
[13] Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179.
[14] JCS Joint Working Group (2010) Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease (JCS 2008)-Digest Version. Circulation Journal, 74, 1989-2020. [Google Scholar] [CrossRef] 
[15] 张胜, 梁雪. 川崎病治疗研究进展[J]. 国际儿科学杂志, 2018, 45(8): 584-588.
[16] Eleftheriou, D., Levin, A.M., Shingadia, D., et al. (1988) Management of Kawasaki Disease. The Journal of Pediatrics, 113, 1116-1117. [Google Scholar] [CrossRef] 
[17] Sundel, R.P., Burns, J.C., Baker, A., et al. (1993) Gamma Globulin Re-Treatment in Kawasaki Disease. Journal of Pediatrics, 123, 657-659. [Google Scholar] [CrossRef] 
[18] Simic, M. (1999) Corticosteroids in the Treatment of the Acute Phase of Kawasaki Disease. Journal of Pediatrics, 135, 465-469. [Google Scholar] [CrossRef] 
[19] Sundel, R.P., Baker, A.L., Fulton, D.R., et al. (2003) Corticosteroids in the Initial Treatment of Kawasaki Disease: Report of a Randomized Trial. The Journal of Pediatrics, 142, 611-616. [Google Scholar] [CrossRef] [PubMed]
[20] Inoue, Y., Okada, Y., Shinohara, M., et al. (2006) A Multicenter Prospective Randomized Trial of Corticosteroids in Primary Therapy for Kawasaki Disease: Clinical Course and Coronary Artery Outcome. Journal of Pediatrics, 149, 336-341. [Google Scholar] [CrossRef] [PubMed]
[21] Kobayashi, T., Saji, T., Otani, T., et al. (2012) Efficacy of Immunoglobulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease (RAISE Study): A Randomized, Open-Label, Blinded-End- points Trial. The Lancet, 379, 1613-1620. [Google Scholar] [CrossRef] 
[22] Chen, S., Dong, Y. and Marcio, G.K. (2016) Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-Analysis. JAMA Pediatrics, 170, 1156-1163. [Google Scholar] [CrossRef] [PubMed]
[23] Wardle, A.J., Kiddy, H.C., Seager, M.J., et al. (2014) Corticosteroids for the Treatment of Kawasaki Disease in Children. Cochrane Database of Systematic Reviews, No. 8, CD011188. [Google Scholar] [CrossRef] 
[24] Chen, S., Dong, Y., Yin, Y., et al. (2013) Intravenous Immunoglobulin plus Corticosteroid to Prevent Coronary Artery Abnormalities in Kawasaki Disease: A Meta-Analysis. Heart, 99, 76-82. [Google Scholar] [CrossRef] [PubMed]

为你推荐